Emanuel Petricoin Describes Screening With Biomarkers

Emanuel F. Petricoin, III, PhD
Published: Tuesday, Apr 16, 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Research is constantly being conducted for new biomarkers, especially for use in detection and predictive value for screening and imaging. Biomarkers can also enhance recurrence monitoring and help to understand treatment efficacy in patients with advanced disease, according to Petricoin.

Most research looks at biomarkers in general population screening but many recently-approved biomarkers for recurrence monitoring have been used for disease.
 
Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Research is constantly being conducted for new biomarkers, especially for use in detection and predictive value for screening and imaging. Biomarkers can also enhance recurrence monitoring and help to understand treatment efficacy in patients with advanced disease, according to Petricoin.

Most research looks at biomarkers in general population screening but many recently-approved biomarkers for recurrence monitoring have been used for disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x